ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, has announced a significant move to distribute shares of its subsidiary, AiBtl BioPharma Inc., as a dividend to its shareholders. This decision, approved by the Board of Directors, marks ABVC's first dividend payment, reflecting the company's confidence in AiBtl's growth potential and its commitment to enhancing shareholder value. Each ABVC shareholder will receive one share of AiBtl for every share of ABVC common stock they own, with an expected distribution of approximately 15 million AiBtl shares.
The distribution is contingent upon the AiBtl shares being included in an effective registration statement under the Securities Act of 1933. ABVC's majority stake in AiBtl, at 57.8%, underscores the strategic importance of this subsidiary in ABVC's portfolio, particularly in advancing its CNS programs for MDD and ADHD markets in the Asia-Pacific region. This move not only rewards shareholders but also strengthens ABVC's position in international business development and partnerships with global pharmaceutical companies.
Dr. Uttam Patil, ABVC's Chief Executive Officer, expressed pride in the company's progress and its ability to offer this dividend, highlighting the long-term potential of AiBtl and ABVC's dedication to shareholder value. This announcement is a testament to ABVC's growth trajectory and its strategic initiatives in the biopharmaceutical industry, potentially setting a precedent for future shareholder rewards and company milestones.
